Enrique M Ocio

Summary

Affiliation: Universidad de Salamanca
Country: Spain

Publications

  1. doi Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry
    Enrique M Ocio
    University Hospital of Salamanca, Cancer Research Center IBMCC CSIC, University of Salamanca, Spain
    Clin Lymphoma Myeloma Leuk 11:93-5. 2011
  2. doi Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
    Enrique M Ocio
    University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
    Expert Opin Investig Drugs 21:1075-87. 2012
  3. pmc In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
    Enrique M Ocio
    Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca P San Vicente, 58 182, 37007 Salamanca, Spain
    Haematologica 95:794-803. 2010
  4. ncbi Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena
    Enrique M Ocio
    Servicio de Hematologia, Hospital Universitario de Salamanca, Spain
    Am J Hematol 78:302-5. 2005
  5. doi Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
    Enrique M Ocio
    Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
    Blood 113:3781-91. 2009
  6. ncbi 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
    E M Ocio
    Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Br J Haematol 136:80-6. 2007
  7. doi Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
    Edvan de Queiroz Crusoe
    Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
    Ann Hematol 91:257-69. 2012
  8. pmc CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
    Teresa Paíno
    Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Salamanca, Spain
    Haematologica 97:1110-4. 2012
  9. pmc Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication
    Irena Misiewicz-Krzeminska
    Servicio de Hematologia, Hospital Universitario, IBSAL, IBMCC USAL CSIC, Salamanca, Spain
    Haematologica 98:640-8. 2013
  10. doi The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
    Enrique Colado
    Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 93:57-66. 2008

Collaborators

Detail Information

Publications31

  1. doi Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry
    Enrique M Ocio
    University Hospital of Salamanca, Cancer Research Center IBMCC CSIC, University of Salamanca, Spain
    Clin Lymphoma Myeloma Leuk 11:93-5. 2011
    ..62 (P<.001). Moreover, in the absence of a BM trephine biopsy, the cut-off points that would help in the differential diagnosis between MGUS, aWM, and sWM would be 20% for morphology and 5% for FCM, both assessed in the BM aspirate...
  2. doi Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
    Enrique M Ocio
    University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
    Expert Opin Investig Drugs 21:1075-87. 2012
    ....
  3. pmc In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
    Enrique M Ocio
    Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca P San Vicente, 58 182, 37007 Salamanca, Spain
    Haematologica 95:794-803. 2010
    ..We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile...
  4. ncbi Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena
    Enrique M Ocio
    Servicio de Hematologia, Hospital Universitario de Salamanca, Spain
    Am J Hematol 78:302-5. 2005
    ..Interestingly, Raynaud phenomenon disappeared under treatment and no new hemolytic events occurred. Anti-CD20 antibody treatment could be an attractive therapeutic approach for MCD, mainly when immune-related disorders are associated...
  5. doi Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
    Enrique M Ocio
    Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
    Blood 113:3781-91. 2009
    ..The potent in vitro and in vivo antimyeloma activity of Zalypsis uncovers the high sensitivity of tumor plasma cells to DSBs and strongly supports the use of this compound in MM patients...
  6. ncbi 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
    E M Ocio
    Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Br J Haematol 136:80-6. 2007
    ..Finally, the survival analysis did not show differences between the two groups of patients, probably due to the short follow up of our series...
  7. doi Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
    Edvan de Queiroz Crusoe
    Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
    Ann Hematol 91:257-69. 2012
    ..Some of these results were further confirmed by apoptosis and cell cycle experiments and also by Western blot and PCR. These data provide the rationale for the use of this novel combination in MM patients...
  8. pmc CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
    Teresa Paíno
    Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Salamanca, Spain
    Haematologica 97:1110-4. 2012
    ..These results do not support CD20 expression for the identification of myeloma cancer stem cells...
  9. pmc Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication
    Irena Misiewicz-Krzeminska
    Servicio de Hematologia, Hospital Universitario, IBSAL, IBMCC USAL CSIC, Salamanca, Spain
    Haematologica 98:640-8. 2013
    ..In conclusion, MiR-214 functions as a tumor suppressor in myeloma by positive regulation of p53 and inhibition of DNA replication...
  10. doi The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
    Enrique Colado
    Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 93:57-66. 2008
    ..We investigated the effects of bortezomib on the growth and survival of AML cells...
  11. ncbi The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
    Patricia Maiso
    Centro de Investigacion del Cancer, Consejo Superior de Investigaciones Cientificas, Universidad de Salamanca, Spain
    Cancer Res 66:5781-9. 2006
    ..Moreover, overexpression of Bcl-X in multiple myeloma cells prevented LBH589-induced cell death. All these data indicate that LBH589 could be a useful drug for the treatment of multiple myeloma patients...
  12. ncbi Cell cycle analysis of Waldenstrom's macroglobulinemia
    Enrique M Ocio
    Hematology Service, Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    Clin Lymphoma 5:250-2. 2005
    ..8% cells in S phase or G2/M phase. In summary, the cell cycle analysis showed that IgM monoclonal gammopathies are low-proliferative disorders, with a DNA ploidy pattern (diploid) clearly different from that of multiple myeloma...
  13. pmc Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
    Enrique Colado
    Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
    Haematologica 96:687-95. 2011
    ..We investigated the antileukemic activity and mechanism of action of zalypsis, a novel alkaloid of marine origin...
  14. doi The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells
    Patricia Maiso
    Centro de Investigacion del Cancer, CSIC Universidad de Salamanca, Spain
    Br J Haematol 141:470-82. 2008
    ..Finally, NVP-AEW541 induced cell death through caspase-dependent and -independent mechanisms. All these data, suggest the potential effect of IGF-IR kinase inhibitors as therapeutic agents for MM patients...
  15. pmc Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects
    Antonio Garcia-Gomez
    Centro de Investigacion del Cancer, IBMCC, Universidad de Salamanca CSIC, Salamanca, Spain
    PLoS ONE 7:e34914. 2012
    ..We aimed to further pre-clinically evaluate the effects of dasatinib (BMS-354825), a multitargeted tyrosine kinase inhibitor, on osteoblast and osteoclast differentiation and function...
  16. pmc Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
    Roberto J Pessoa de Magalhães
    Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 98:79-86. 2013
    ....
  17. doi Novel generation of agents with proven clinical activity in multiple myeloma
    Maria Victoria Mateos
    Haematology Department, University Hospital of Salamanca, Cancer Research Center IBMCC CSIC, University of Salamanca, Institute of Biomedical Research of Salamanca IBSAL, Spain Electronic address
    Semin Oncol 40:618-33. 2013
    ....
  18. doi New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
    Enrique M Ocio
    Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Lancet Oncol 9:1157-65. 2008
    ..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents...
  19. doi Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
    Teresa Paíno
    Centro de Investigacion del Cancer, Instituto de Biología Molecular y Celular del Cáncer Consejo Superior de Investigaciones Científicas Universidad de Salamanca, Salamanca, Spain Instituto de Investigación Biomédica de Salamanca IBSAL, Salamanca, Spain
    PLoS ONE 9:e92378. 2014
    ..Future characterization of clonal plasma cell subpopulations in MM patients' samples will guarantee the discovery of more reliable markers able to discriminate true clonogenic myeloma cells...
  20. doi RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
    Antonio Garcia-Gomez
    Centro de Investigacion del Cancer, IBMCC Universidad de Salamanca CSIC, Campus Miguel de Unamuno, Avda Coimbra s n, 37007 Salamanca, Spain
    Invest New Drugs 31:200-5. 2013
    ..Also, vascular endothelial growth factor (VEGF) may greatly influence OC formation and resorption through VEGFR1 and VEGFR2. RAF265 is a novel, orally bioavailable dual inhibitor of RAF kinase and VEGFR2...
  21. doi Novel treatment regimens for Waldenström's macroglobulinemia
    Ramon Garcia-Sanz
    University Hospital of Salamanca, Universidad de Salamanca Consejo Superior de Investigaciones Cientificas, Paseo de San Vicente 58 182, Salamanca 37007, Spain
    Expert Rev Hematol 3:339-50. 2010
    ..Here we review the most recent results reported for the use of new combinations and new drugs in patients with WM at different stages of the disease...
  22. doi The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
    Bruno Paiva
    Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, Salamanca, Spain
    Blood 117:3613-6. 2011
    ..01). MFC immunophenotyping could be clinically useful for the demonstration of PC clonality in AL and for the prognostication of patients with AL...
  23. pmc The DAC system and associations with multiple myeloma
    Enrique M Ocio
    University Hospital of Salamanca, Salamanca, Spain
    Invest New Drugs 28:S28-35. 2010
    ..This has prompted the development of combinations such as the one with bortezomib or lenalidomide and dexamethasone, which have already been taken into the clinics with positive preliminary results...
  24. ncbi Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma
    Enrique M Ocio
    Hematology Service, Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    Clin Lymphoma 5:241-5. 2005
    ..Interestingly, the incidence of IgH rearrangement was low in WM (12%) and SMZL (10%). Immunophenotypic and molecular cytogenetic studies could help to distinguish WM from SMZL...
  25. doi Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy
    Xi Chen
    Corresponding Author Atanasio Pandiella, Instituto de Biologia Molecular y Celular del Cancer, Campus Miguel de Unamuno, 37007 Salamanca, Spain
    Mol Cancer Ther 13:504-16. 2014
    ..Together, our data support the clinical development of agents that widely target mTOR, instead of agents, such as rapamycin or its derivatives, that solely act on mTORC1...
  26. ncbi Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
    N C Gutierrez
    Servicio de Hematologia, Hospital Universitario de Salamanca and Centro de Investigación del Cáncer CIC, Universidad de Salamanca CSIC, Salamanca, Spain
    Leukemia 21:541-9. 2007
    ..In addition, three of the target genes activated by PAX5 - CD79, BLNK and SYK - were upregulated in WM-PC. In summary, these results indicate that both PC and BL from WM are genetically different from the MM and CLL cell counterpart...
  27. ncbi Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
    Eva Kimby
    Karolinska University Hospital, Stockholm, Sweden
    Clin Lymphoma Myeloma 6:380-3. 2006
    ..The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease...
  28. doi p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:598-606. 2008
    ..These results suggest that LY represents a promising novel targeted approach to improve MM patient outcome both by enhancing the effect of bortezomib and by reducing osteoskeletal events...
  29. doi Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:5216-25. 2008
    ..The profile of the anti-MM activity of Aplidin in our preclinical models provided the framework for its clinical testing in MM, which has already provided favorable preliminary results...
  30. ncbi Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute LG102, 44 Binney Street, Boston, MA 02115, USA
    Blood 107:3442-6. 2006
    ....
  31. ncbi 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
    Tanyel Kiziltepe
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 6:1718-27. 2007
    ..Taken together, these data provide the preclinical rationale for the clinical evaluation of 5-azacytidine, alone and in combination with doxorubicin and bortezomib, to improve patient outcome in MM...